Oral Answers to Questions

Debate between Jo Churchill and Lord Johnson of Marylebone

Tuesday 12th September 2017 Commons Chamber

[Jo Churchill (Bury St Edmunds) (Con)]

T3. The life sciences industry is worth £64 billion to the UK, and Sir John Bell’s report last week indicated how important manufacturing was. Will the Minister therefore join me in welcoming the opening of the cell and gene manufacturing unit and welcome further jobs in this industry in the east of England, particularly in my constituency?

[The Minister for Universities, Science, Research and Innovation (Joseph Johnson)]

We indeed welcome that. Medicines manufacturing is key, which is why we have launched a £146 million medicines manufacturing programme under the industry strategy challenge fund. That includes £12 million for expansion of the cell and gene therapy manufacturing centre. The other centres, a vaccines centre, a medicines manufacturing innovation centre and three advanced therapy centres, are open to competition and could be located anywhere in the country, including in the east of England.

Higher Education and Research Bill (Thirteenth sitting)

Debate between Jo Churchill and Lord Johnson of Marylebone

Committee Debate: 13th sitting: House of Commons
Tuesday 18th October 2016 Public Bill Committees

[Jo Churchill (Bury St Edmunds) (Con)]

I listened to what the hon. Member for Sheffield Central said, and I contend that it is purely by having a flexible, open system that the things he asks for are actually possible. The problems within the system that he articulated are often due to the inadequacies of the departments involved. I know that because I have been closely affected by it. Allowing institutions to work with these overarching bodies but driving quality from the institutions themselves is what is wanted. Furthermore, an individual benefits from being asked to teach. It is not always detrimental for a researcher to expand their skills in that way.

[Joseph Johnson]

In answer to the question from the hon. Member for Sheffield Central on the teaching excellence framework and postgrad research, in the first instance, no, it will not deal with the postgrad experience; it focuses on undergrad and part-time. The Bill sets out clear responsibilities for UKRI and the OFS, with the OFS being the regulator for all students, including at postgraduate level.

There are a number of areas that will require close co-operation between UKRI and the OFS, including on postgraduates, and it is vital that they are empowered to work together. The Bill does that through clause 103, which enables and ensures joint working, co-operation and the sharing of information. An emphasis on working together will run through the leadership and management of both organisations, supported by a legal framework that will be sufficiently flexible to deal effectively with areas of shared interest.

Education, Skills and Training

Debate between Jo Churchill and Lord Johnson of Marylebone

Wednesday 25th May 2016 Commons Chamber

[Joseph Johnson]

The right hon. Gentleman should wait a little bit longer to see the full fruits of the work of the Skills Minister, my hon. Friend the Member for Grantham and Stamford (Nick Boles), and colleagues in the Department for Education led by the expert panel that is chaired by Lord Sainsbury.

To return to the question of why our higher education system needs to meet new challenges, the system needs to be more innovative to meet the diverse needs of learners of all ages and employers of all sizes. As promised in our manifesto, we will promote more flexible learning with the provision of, for example, two-year degrees and degree apprenticeships. We need the system to deliver better outcomes for those who go through it and for the taxpayers who underwrite it. While employers suffer skills shortages, especially in highly skilled STEM areas, at least 20% of graduates wind up in non-professional roles three and a half years after graduating. This graduate labour market mismatch is a waste of their potential and a brake on our economic productivity.

[Jo Churchill (Bury St Edmunds) (Con)]

Does my hon. Friend agree that it is also important to use our local enterprise partnerships to invigorate places where those needs exist and work out how we can meet them? My hon. Friend the Member for South Suffolk (James Cartlidge) has mentioned the new University of Suffolk campus, and West Suffolk College, in my constituency, has just received an £8 million stimulus from our New Anglia local enterprise partnership.

[Joseph Johnson]

We certainly agree with all that. Universities are at the heart of many of the most successful LEPs, and we want their good work to stimulate economic growth and relevant provision of higher education by universities in their local areas. That is why at the heart of the Bill are powers to make it easier for high-quality new universities and challenger institutions to enter the sector and award degrees, to drive up quality and to give applicants more choice about where and how to study.

Some say, “Close the door to new universities. Put the cap back on student numbers. Restrict the benefits of higher education to a narrow elite.” The same arguments have been made at every period of university expansion. In the 1820s, University College London and King’s were dismissed as “cockney” universities. Today, they are globally renowned. Those arguments were heard when the civic colleges in Manchester, Birmingham, Liverpool, Leeds, Sheffield and Bristol became red-brick universities before the first world war, and when the Conservative Government of John Major took through Parliament the 1992 legislation that created a wave of new universities from the polytechnics.

UK Science Budget

Debate between Jo Churchill and Lord Johnson of Marylebone

Wednesday 21st October 2015 Westminster Hall

[The Minister for Universities and Science (Joseph Johnson)]

It is a pleasure to serve under your chairmanship, Sir Roger. I congratulate my hon. Friend the Member for Pudsey (Stuart Andrew) on securing the debate on a subject that is being explored in great detail at the moment by the Science and Technology Committee. I am glad to see the Chair, my hon. Friend the Member for Oxford West and Abingdon (Nicola Blackwood), here, along with other members of the Committee.

My hon. Friend the Member for Pudsey raised the issue of medical research and the contributions of the British Heart Foundation to that. I was pleased earlier this month to see BHF employees in Manchester during the Conservative party conference, and I enjoyed looking at their stand and hearing at first hand about the high-quality research that the organisation is doing on cardiovascular diseases. The BHF’s research remains one of this country’s great success stories, and it has a long history going all the way back to the pioneering heart surgery technique for babies developed by Professor Sir Magdi Yacoub in the 1970s, which is still used today, all the way through to the more recent and ongoing improvements in heart attack diagnosis that are helping to save lives in Britain and across the world.

Research investment in medicine and cardiovascular disease is an important illustration of the strength of our science base. The investment we are making as a country through charities, Government and pharmaceutical companies is helping to ensure that Britain remains at the forefront of science and research in Europe and throughout the world. I should like to point out a few examples of that investment. The Medical Research Council currently spends around £20 million a year. That, coupled with the £49 million spent by the National Institute for Health Research, which is funded by the Department of Health, makes the UK the top contributor among EU member states to cardiovascular research. We are building on that base. This year, we committed to fund the Academy of Medical Sciences, alongside the other national academies, for the first time, granting it £0.5 million.

[Jo Churchill (Bury St Edmunds) (Con)]

We are talking about what we are spending, but we are not talking about what we are saving. We are developing the life sciences, agritech—agritech is hugely important to rural constituencies such as mine, and my constituency is on the edge of the Cambridge phenomenon—biotech, digital health and so on, and we need to take those savings into consideration. If we lose that research abroad, we will lose the savings, too.

[Joseph Johnson]

Indeed, this is a good investment, which is why the Government have been supporting our science base over time. We recognise the huge economic benefits that it brings to the country.

I was in the middle of describing the investments we are making in cardiovascular and other medical technologies research. We have supplemented the ongoing spending of the MRC and the NIHR by announcing a couple of new innovation institutions, which will be extremely helpful to the sector in developing new medical technologies. We have just announced a new medicines technologies catapult, which will be based at Alderley Park in Cheshire. We have also announced the headquarters of the new precision medicine catapult in Cambridge, which will have one of its five centres of excellence in the north of England. The hon. Member for Cambridge (Daniel Zeichner) focused on excellence in Cambridge. I am happy to tell him that I was in Cambridge last week and saw the laboratory of molecular biology. I was as impressed as his comments would have led me to expect—it is an extraordinary centre, and we have every intention of continuing to ensure that it remains one of the world’s leading research institutes.

The examples that Members have already cited, such as Cambridge and the scientific centres in the northern powerhouse, are good examples of why Britain is such a powerhouse in the world of science and why we want to ensure that we make Britain the best place in the world to do science. Our global scientific impact is completely out of proportion with both our population and the size of our research spend as a share of global research and development expenditure. The UK punches well above its weight.